Summary of Study ST002941
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001830. The data can be accessed directly via it's Project DOI: 10.21228/M85H91 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST002941 |
Study Title | Targeted analyses of microbial metabolites of xanthohumol |
Study Summary | The Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The aim of this study was to quantify major microbial metabolites of xanthohumol. |
Institute | Oregon State University |
Last Name | Jamieson |
First Name | Paige |
Address | 307 LINUS PAULING SCIENCE CTR |
jamiesop@oregonstate.edu | |
Phone | 5417379804 |
Submit Date | 2023-10-22 |
Num Groups | 2 |
Total Subjects | 27 |
Analysis Type Detail | LC-MS |
Release Date | 2024-01-01 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001830 |
Project DOI: | doi: 10.21228/M85H91 |
Project Title: | Targeted analyses of microbial metabolism for the XMaS clinical trial |
Project Summary: | The Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The main objective was to examine clinical safety and subjective tolerability of xanthohumol compared to placebo. Additional aims were to monitor biomarkers of inflammation, gut permeability, bile acid metabolism, short-chain fatty acids, and metabolism of xanthohumol. |
Institute: | Oregon State University |
Last Name: | Jamieson |
First Name: | Paige |
Address: | 307 LINUS PAULING SCIENCE CTR |
Email: | jamiesop@oregonstate.edu |
Phone: | 5417379804 |